MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety.
暂无分享,去创建一个
[1] H. Schmitt-Willich. Stability of linear and macrocyclic gadolinium based contrast agents. , 2007, The British journal of radiology.
[2] Shao-Pow Lin,et al. MR contrast agents: Physical and pharmacologic basics , 2007, Journal of magnetic resonance imaging : JMRI.
[3] Gerald A Kirk,et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. , 2007, AJR. American journal of roentgenology.
[4] S. Cowper,et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[5] E. Yucel,et al. A Summary of Safety of Gadofosveset (MS-325) at 0.03 mmol/kg Body Weight Dose: Phase II and Phase III Clinical Trials Data , 2006, Investigative radiology.
[6] Lone Skov,et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.
[7] Yoshiaki Tanaka,et al. Dialyzability of gadodiamide in hemodialysis patients , 2006, Radiation Medicine.
[8] Sophie Laurent,et al. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.
[9] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] R. Prayson,et al. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. , 2006, Archives of pathology & laboratory medicine.
[11] R. Elenitsas,et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema , 2005, Journal of cutaneous pathology.
[12] S. Jimenez,et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.
[13] S. Cowper. Nephrogenic fibrosing dermopathy: the first 6 years , 2003, Current opinion in rheumatology.
[14] D. Cohen,et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). , 2003, Journal of the American Academy of Dermatology.
[15] M. Lockhart,et al. Imaging of adrenal masses. , 2002, European journal of radiology.
[16] P. Leboit,et al. Nephrogenic Fibrosing Dermopathy , 2001, The American Journal of dermatopathology.
[17] P. Leboit,et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.
[18] L. Schad,et al. Elimination of gadolinium-DTPA by peritoneal dialysis. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[19] M. Taupitz,et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.